#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Immunotherapy Adverse Events in the Treatment of Solid Tumors


Authors: Soňa Karas Křivonosková 1;  Tomáš Mačinga 1;  Anna Opluštilová 1;  Blanka Rosová 2;  Radka Lohynská 1;  Ludmila Boublíková 1
Authors‘ workplace: Onkologická klinika 1. lékařské fakulty Univerzity Karlovy a Fakultní Thomayerovy nemocnice, Praha 1;  Ústav patologie a molekulární medicíny 3. lékařské fakulty Univerzity Karlovy a Fakultní Thomayerovy nemocnice, Praha 2
Published in: Čes.-slov. Patol., 62, 2026, No. 3, p. 201-207
Category: Reviews Article

Overview

Immune checkpoint inhibitors (ICIs) are the mainstay of therapy for many malignancies and fundamentally improve the prognosis of oncology patients. However, they carry the risk of immune-related adverse events (irAEs) due to the loss of peripheral immune tolerance, which can affect various tissues and organs. These events can occur at any time during or after treatment, although some follow a typical temporal pattern, and may exert various grades, from mild to lifethreatening. The probability and severity of irAEs are not directly dose-dependent as with conventional chemotherapy, but are related to other factors –⁠ such as the combination of different types of ICIs. Differentiating an irAE from infectious complications or tumor progression can be clinically challenging. This paper highlights the crucial role of histological verification and close cooperation with a pathologist for safe therapy administration. Within a case report of a patient with generalized clear cell renal cell carcinoma on long-term treatment with a combination of ICIs (nivolumab and ipilimumab), we present a comprehensive diagnostic and therapeutic approach to various gradually developing irAEs. Histological verification of atypical lesions is a key tool in this context for accurate diagnosis, targeted administration of immunosuppression, and the prevention of fatal complications.

Keywords:

immunotherapy – Renal cell carcinoma – immune-related adverse events


Sources

1. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18(3): e143-52.

2. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378(2): 158-68.

3. Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford) 2019; 58(Suppl 7): vii59-67.

4. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33(12): 1217-38.

5. National Comprehensive Cancer Network (NCCN). (2026). NCCN Guidelines: Management of Chceckpoint Inhibitor-related Toxicities. Version 1.2026 [online]. NCCN. Retrieved November 4,2026 dostupné z: https://www. nccn.org/professionals/physician_gls/pdf/ ici_tox.pdf

6. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28(2): 368-76.

7. Státní ústav pro kontrolu léčiv. YERVOY 5MG/ML INF CNC SOL 1X10ML (kód SÚKL: 0185101) -⁠ Indikační omezení úhrady. Přehledy léčiv SÚKL. Citováno 29. května, 2026. https://prehledy.sukl.cz/prehled_leciv.html#/ leciva/0185101

8. Státní ústav pro kontrolu léčiv. OPDIVO 10MG/ML INF CNC SOL 1X10ML (kód SÚKL: 0210773) -⁠ Indikační omezení úhrady. Přehledy léčiv SÚKL. Citováno 29. května, 2026. https://prehledy.sukl.cz/prehled_leciv.html#/ leciva/0210773

9. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019; 7(1): 306.

10. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Accessed November 2, 2022. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_ v5_Quick_Reference_5x7.pdf

11. Česká onkologická společnost ČLS JEP. Modrá kniha České onkologické společnosti. Linkos. Citováno 3. dubna 2026. https://www. linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/

12. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21): 2691-7.

13. Osorio JC, Ni A, Chaft JE, et al. Antibody -⁠ -mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28(3): 58389.

14. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99(11): 4078-85.

15. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol 2018; 19(3): 345-61.

16. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83(5): 1255-68.

17. Vivar KL, Deschaine M, Messina J et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017; 44 : 381–4.

18. Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018; 6(1): 95.

19. Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer 2017; 86 : 248-56.

20. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68(6): 1181 -⁠ 90.

21. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2017; 35(7): 709-17.

22. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90(3): 638-47.

23. Mahmood SS, Fradley mg, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71(16): 1755-64.

24. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‚take the brakes off‘ the immune system. Ther Adv Neurol Disord 2018; 11 : 1756286418799864.

25. Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 2019; 122 : 72-90.

26. Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021; 80(1): 36-48.

27. Tannir NM, Albigès L, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024; 35(11): 1026-38.

28. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021; 385(8): 683-94.

29. Garon, E. B., et al. „CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after  ≤  12 months of nivo in previously treated advanced NSCLC.“ Journal of Clinical Oncology 37.8_suppl (2019): 100-100.

30. Elijah, J., et al. „Evaluation of safety outcomes between nivolumab regimens with differing dosing patterns.“ Journal of Oncology Pharmacy Practice 31.6 (2025): 895-901.

31. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378(2): 158-68.

Labels
Anatomical pathology Forensic medical examiner Toxicology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#